New Delhi, September 3rd, 2025: Poly Medicure Ltd. (NSE: POLYMED | BSE: 531768), India’s leading Medical Device company with a dominant position in medical consumables market, today announced signing of definitive agreements to acquire 90% stake in PendraCare Group consisting of PendraCare Holdings and Wellinq Medical from Wellinq Holdings B.V.

新德里，2025年9月3日：印度领先的医疗器械公司Poly Medicure Ltd.（NSE: POLYMED | BSE: 531768），在医疗耗材市场占据主导地位，今天宣布已签署最终协议，收购PendraCare集团90%的股份，该集团包括PendraCare Holdings和Wellinq Medical，卖方为Wellinq Holdings B.V.。

at an Enterprise value of ₹188.5 crores (Euro 18.3mn). The balance 10% stake to be acquired in 2030 basis actual EBITDA for CY 2029. PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s.

企业价值为188.5亿卢比（1830万欧元）。剩余10%的股份将于2030年根据2029年的实际息税折旧摊销前利润（EBITDA）收购。PendraCare集团开发、制造并销售创新型心脏病学导管解决方案，同时为其他全球原始设备制造商（OEM）提供设计、开发和制造服务。

This “bolt-on” acquisition provides Polymed with an opportunity to scale its cardiology business globally with immediate access to world’s most regulated markets of Europe and the US..

这项“附加”收购为Polymed提供了将其心脏病学业务扩展到全球的机会，并立即进入欧洲和美国这些全球最受监管的市场。

Strategic Rationale for Acquisition

收购的战略理由

Strategic Asset: The Group is one of the few independent cardiology ancillary consumable businesses in Europe. It fits well with Polymed’s strategy to grow cardiology business through strong R&D and manufacturing capabilities in ancillary cardiology consumables segment.

战略资产：该集团是欧洲为数不多的独立心脏病学辅助耗材业务之一。它与Polymed通过在心脏病学辅助耗材领域的强大研发和制造能力来发展心脏病业务的战略非常契合。

Regulatory approvals in key markets: Products registered in Europe (MDD and MDR), FDA, ANVISA, CFDA, KFDA and multiple local country registrations

关键市场的监管批准：产品在欧洲（MDD和MDR）、FDA、ANVISA、CFDA、KFDA以及多个国家的当地注册已获批。

Made in Europe: Established European manufacturing base, enabling localized production and distribution of products.

欧洲制造：建立欧洲生产基地，实现产品的本地化生产和分销。

Existing relationships with global med-tech OEM’s: Over decade long relationship with large global OEM’s

与全球医疗技术原始设备制造商的现有关系：与大型全球原始设备制造商拥有超过十年的关系

Platform for Global expansion: Provides a platform to globally scale our cardiology business— leveraging local manufacturing, regulatory approvals, existing product lines, distribution, and operational capabilities of the Group.

全球扩展平台：提供了一个平台，以扩大我们的心脏病学业务规模——利用集团的本地制造、监管批准、现有产品线、分销和运营能力。

Synergies: Potential to generate EUR 3-4 million of annual synergies in next 3-4 years through following levers:

协同效应：通过以下杠杆措施，在未来3-4年内有望实现每年300-400万欧元的协同效应：

Leveraging Polymed’s engineering, R&D and manufacturing capabilities to drive innovation and cost efficiencies

利用Polymed的工程、研发和制造能力来推动创新和成本效率。

Expansion of distribution network through Polymed’s global relationships o Leveraging Pendracare’s existing customer relationships to drive Polymed’s

通过Polymed的全球关系网扩展分销网络，利用Pendracare现有的客户关系推动Polymed的业务。

cardiology product sales

心脏病学产品销售

Deepen presence in Europe for existing and new product launches

深化在欧洲的现有和新产品发布的影响力

Transaction Structure Overview:

交易结构概述：

PendraCare Group Proforma Financials: CY24 Revenue: EUR 9.9 million I Gross Profit: EUR 7.3 million I EBITDA: EUR 1.4 million I PBT : EUR 801k

PendraCare集团预测财务数据：2024年收入：990万欧元 | 毛利润：730万欧元 | 息税折旧摊销前利润（EBITDA）：140万欧元 | 税前利润（PBT）：80.1万欧元

Existing Management to continue to lead the business; Sander Hartman to remain as the CEO, who will continue to hold 10% non-voting shares in the Group

现有管理层将继续领导公司业务；桑德·哈特曼将继续担任首席执行官，并继续持有集团10%的无投票权股份。

Enterprise value of the company of ~Euro 18.3mn at first closing valuing the company at EV/Revenue and EV/EBITDA (FY 2024) of 1.83x and 13x respectively

公司企业价值约为1830万欧元，在首次交割时对公司估值为EV/收入和EV/EBITDA（2024财年）分别为1.83倍和13倍。

Certain earn-out payments to be made subject to achievement of defined milestones over the next 4-5 years

在未来的4到5年内，根据定义的里程碑达成情况，需支付特定的盈利支付款项。

Balance 10% stake to be acquired in 2030 basis actual EBITDA of CY 2029The acquisition is subject to customary closing conditions and approvals and is expected to

余额10%的股份将于2030年根据2029年的实际息税折旧摊销前利润（EBITDA）进行收购。该收购需符合惯例的交割条件和审批，并预计

be closed in next 4-8 weeks

在未来4到8周内关闭

Commenting on the acquisition, Mr. Himanshu Baid, Managing Director, Poly Medicure Limited stated:

宝莱医疗有限公司董事总经理Himanshu Baid先生在评论此次收购时表示：

We are thrilled to announce the acquisition of Pendracare group, a unique Interventional Cardiology consumable business in Europe. This move brings us a valuable, ‘made-in-Europe’ cardiology consumables business with FDA and CE-marked products and long-term relationships with global OEMs. By combining Pendracare Group’s European presence and customer relationships with Polymed’s strong engineering, R&D, manufacturing and distribution capabilities, we believe we will deliver significant synergies for the combined business.

我们非常高兴地宣布收购了Pendracare集团，这是一家在欧洲独具特色的介入心脏病学耗材业务公司。此次收购为我们带来了一家宝贵的“欧洲制造”心脏科耗材业务，其产品拥有FDA和CE认证，并与全球原始设备制造商建立了长期合作关系。通过将Pendracare集团在欧洲的市场存在和客户关系，与Polymed强大的工程、研发、制造和分销能力相结合，我们相信将为合并后的业务带来显著的协同效应。

Most importantly, it deepens our presence in Europe – a key market for Polymed. This acquisition helps in furthering our vision of “Serving people through innovative healthcare solutions”..

最重要的是，它加深了我们在欧洲的存在——这是Polymed的一个关键市场。这次收购有助于进一步实现我们“通过创新的医疗解决方案服务人民”的愿景。

Commenting on the acquisition, Mr. Floris Alkemade (Founder) and Sander Hartman (CEO) stated:

关于此次收购，弗洛里斯·阿尔克马德先生（创始人）和桑德·哈特曼（首席执行官）表示：

We have great confidence in Polymed Group as the right partner for the future of PendraCare. We sincerely thank our teams for their dedication and achievements, which have laid a strong foundation for this next step. We look forward being part of Polymed Group and together we will continue to focus on developing and delivering the highest-quality medical devices, ensuring lasting benefits for users and patients worldwide..

我们对Polymed集团作为PendraCare未来发展的正确合作伙伴充满信心。我们衷心感谢团队的奉献与成就，为这一下一步奠定了坚实的基础。我们期待成为Polymed集团的一员，并将继续专注于开发和提供最高质量的医疗设备，为全球用户和患者带来持久的利益。